blonanserin has been researched along with apomorphine in 2 studies
| Studies (blonanserin) | Trials (blonanserin) | Recent Studies (post-2010) (blonanserin) | Studies (apomorphine) | Trials (apomorphine) | Recent Studies (post-2010) (apomorphine) |
|---|---|---|---|---|---|
| 121 | 21 | 93 | 9,205 | 287 | 780 |
| Protein | Taxonomy | blonanserin (IC50) | apomorphine (IC50) |
|---|---|---|---|
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | 0.22 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0146 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D | Rattus norvegicus (Norway rat) | 0.4744 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 0.3385 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(1B) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0813 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.205 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 1.35 | |
| D | Bos taurus (cattle) | 0.3385 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurumiya, S; Miura, Y; Noda, Y; Oka, M | 1 |
| Masui, A; Minamimoto, S; Mizobe, Y; Mizuguchi, Y; Ochiai, M; Ohno, Y; Shimizu, S; Tamura, M; Tatara, A | 1 |
2 other study(ies) available for blonanserin and apomorphine
| Article | Year |
|---|---|
Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Body Temperature; Brain; Drug Synergism; Haloperidol; Male; Piperazines; Piperidines; Rats; Rats, Wistar; Receptors, Dopamine; Veratrine | 1993 |
Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin.
Topics: Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Injections, Subcutaneous; Male; Mice; Nucleus Accumbens; Oncogene Proteins v-fos; Piperazines; Piperidines; Pyridines | 2015 |